Analyst Price Targets — TMCI
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 7, 2026 12:35 pm | — | Stifel Nicolaus | $3.00 | $2.92 | TheFly | Treace Medical price target lowered to $3 from $5 at Stifel |
| December 18, 2025 2:15 pm | Richard Newitter | Truist Financial | $3.00 | $2.54 | TheFly | Treace Medical price target lowered to $3 from $4 at Truist |
| November 10, 2025 3:07 pm | Richard Newitter | Truist Financial | $4.00 | $3.86 | TheFly | Treace Medical price target lowered to $4 from $7 at Truist |
| October 15, 2025 12:47 pm | — | Truist Financial | $7.00 | $6.20 | TheFly | Treace Medical price target lowered to $7 from $8 at Truist |
| September 3, 2025 7:58 pm | — | Truist Financial | $8.00 | $7.25 | TheFly | Treace Medical price target raised to $8 from $6.60 at Truist |
| March 13, 2025 12:19 pm | — | Truist Financial | $9.50 | $7.94 | TheFly | Treace Medical price target lowered to $9.50 from $10 at Truist |
| February 4, 2025 11:06 am | Ryan Zimmerman | BTIG | $16.00 | $10.51 | TheFly | Treace Medical upgraded to Buy from Neutral at BTIG |
| December 31, 2024 12:45 pm | Ben Haynor | Lake Street | $14.50 | $7.44 | TheFly | Treace Medical initiated with a Buy at Lake Street |
| May 16, 2024 4:36 am | Danielle Antalffy | UBS | $6.50 | $5.95 | TheFly | Treace Medical downgraded to Neutral from Buy at UBS |
| September 21, 2022 9:19 am | — | BTIG | $28.00 | $23.95 | Benzinga | BTIG Maintains Buy on Treace Medical Concepts, Raises Price Target to $28 |
Latest News for TMCI
Treace Medical Concepts, Inc. (TMCI) Q2 2026 Earnings Call Transcript
Treace Medical Concepts NASDAQ: TMCI reported second-quarter 2026 revenue of $45.4 million, down 4% from the prior-year period, as lower procedure-kit sales to stocking distributors and a continued shift toward lower-priced minimally invasive products weighed on reported sales.
Treace Medical Concepts (TMCI) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.28 per share a year ago.
PONTE VEDRA, Fla., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related deformities, today reported financial results for the second quarter ended June 30, 2026.
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for TMCI.
U.S. House Trading
No House trades found for TMCI.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.